Physician profile
Ethan E Huisman
NPI 1891776365
$110,945.37
in general payments reported to CMS, 2019-2025
10 companies · $9,312 in 2025
The $9,312 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $6,984 · 2021: $8,664 · 2022: $27K · 2023: $18K · 2024: $18K · 2025: $9,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $17K · Consulting Fee: $6,615 · Food and Beverage: $4,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,870.00 |
| Travel and Lodging | $16,682.11 |
| Consulting Fee | $6,615.00 |
| Food and Beverage | $4,140.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $107,151.38 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $3,206.07 | 2020-2025 | Total30, Dailies Total1, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $202.98 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $128.94 | 2020-2025 | Acuvue |
| Horizon Therapeutics Plc | $88.26 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.46 | 2019-2020 | |
| Dompe US, INC. | $27.43 | 2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $24.34 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Bausch & Lomb Americas INC. | $19.11 | 2023 | Vyzulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Huisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.